ONCOLOGY Vol 13 No 3
-
-
Prostate Cancer Risk Assessment Program
-
Commentary
-
Prostate Cancer Risk Assessment Program
-
International Palliative Care Conference to Be Held in Hong Kong
-
Commentary
-
WHO Declares Lymphatic Mapping to Be the Standard of Care for Melanoma
-
2 Cycles of ABVD Plus Radiotherapy Is More Effective Than Radiotherapy Alone in Early Stage HD—Interim Ahan Radiotherapy Alone in Early Stage HD—Interim Analysis of the HD7 Trial of the GHSG Clinic of Internal Medicine I University of Cologne/Germany
-
Rituximab: Phase II Retreatment Study in Patients With Low-Grade or Follicular Non-Hodgkin’s Lymphoma
-
Use of Brachytherapy to Preserve Function in Children With Soft-Tissue Sarcomas
-
Commentary
-
Response Criteria for NHL: Importance of “Normal” Lymph Node Size and Correlations With Response
-
Commentary
-
Commentary
-
Chemotherapy Plus Radiation Improves Survival in Patients With Cervical Cancer
-
A Randomized Trial of Fludarabine, Mitoxantrone (FM) Versus Doxorubicin, Cyclophosphamide, Vindesine, Prednisone (CHEP) as First Line Treatment in Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma: A Multicenter Study by GOELAMS Group
-
Commentary
-
Commentary
-
Navelbine Increased Elderly Lung Cancer Patients’ Survival
-
Fludarabine Versus Conventional CVP Chemotherapy in Newly C Diagnosed Patients With Stages III and IV Low-Grade Malignant Non-Hodgkin’s Lymphoma: Preliminary Results From a Prospective, Randomized Phase III Clinical Trial in 381 Patients
-
Therapy for Early-Stage Colorectal Cancer
-
Prostate Cancer Risk Assessment Program
-
Treatment of Estrogen Deficiency Symptoms in Women Surviving Breast Cancer, Part 3
-
Multicenter, Phase III Study of Iodine-131 Tositumomab (Anti-B1 Antibody) for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma
-
T-Cell–Depleted Allogeneic Bone Marrow Transplant From HLA-Matched Sibling Donors for Non-Hodgkin’s Lymphoma
-
Use of Brachytherapy to Preserve Function in Children With Soft-Tissue Sarcomas
-
Commentary
-
Consensus Statement on Prevention and Early Diagnosis of Lung Cancer
-
In Vivo Purging and Adjuvant Immunotherapy With Rituximab During PBSC Transplant For NHL
-
Commentary
-
Elderly High-Grade Non-Hodgkin’s Lymphomas: First Line VNCOP-B Regimen Experience in 350 Patients
-
Commentary
-
Therapy for Early-Stage Colorectal Cancer
-
Fludarabine and Cyclophosphamide: A Highly Active and Well-Tolerated Regimen for Patients With Previously Untreated Indolent Lymphomas
-
Commentary
-
Campath-1H Monoclonal Antibody in Therapy for Advanced Low-Grade Non-Hodgkin’s Lymphomas: A Phase II Study
-
Commentary
-
AIDS Drugs Effective Against Most Common HIV Strain
-
Rituximab Therapy in Previously Treated Waldenström’s Macroglobulinemia: Preliminary Evidence of Activity
-
Chimeric Anti-CD20 (C2B8)-Mediated Sensitization of B-Cell Lymphoma to Cytotoxic Agents: Role of C2B8 in Regulating Endogenous IL-10 and Oncogenes
-
Superiority of Allogeneic to Autologous Marrow or Blood Stem Cell Transplantation for Low-Grade Lymphoma
-
IDEC-Y2B8 Radioimmunotherapy: Responses in Patients With Splenomegaly
-
Detection of Minimal Residual Disease by bcl-2 PCR in Early Stage Follicular Lymphomas
-
Prostate Cancer Risk Assessment Program
-
Use of Brachytherapy to Preserve Function in Children With Soft-Tissue Sarcomas
-
Increased Efficacy Through Moderate Dose Escalation of Chemotherapy: Interim Report From the HD9 Randomized Trial for Advanced Hodgkin’s Disease
-
Radiotherapy Versis Chemotherapy as ConsolidativeTreatment for Stage IIIB-IV Hodgkin’s Disease in First Complete Remission or Good Partial Response: A Study of 559 Patients (H89 Protocol)
-
Comparative Economic Analysis of the Treatment of Relapsed Low-Grade B-Cell Non-Hodgkin’s Lymphoma Using CHOP, Fludarabine, or Rituximab
-
Results of High-Dose Therapy and Autologous Stem Cell Transplant in Patients With Stage IV Hodgkin’s Disease: The Impact of Disease Status and Prior Radiotherapy
-
IOM Panel Criticizes NCI Spending on Ethnic Group Research
-
Genes Linked to Early Onset, Distal Location of Hereditary Colon Cancer
-
Spotlight Again on Alternative Therapies
-
Therapy for Early-Stage Colorectal Cancer
-
Efficacy Controls and Long-Term Follow-Up of Patients Treated With Rituximab for Relapsed or Refractory, Low-Grade or Follicular Non-Hodgkin’s Lymphoma
-
CHVP + Interferon-Alfa-2b Treatment Is Associated With a Longer Survival Than Fludarabine Alone in Elderly Patients With High-Risk Follicular Lymphoma: A Randomized Study From the GELA
-
PCR Analysis for the t(14;18) Translocation in Patients With Recurrent Follicular Lymphoma Following Immunotherapy With Rituximab (IDEC-C2B8)
-
Commentary
-
Commentary
-
Arsenic Trioxide in Acute Promyelocytic Leukemia: Results of Initial US Pilot and Multicenter Trials
-
Commentary
-
Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Tumor Lysis
-
In Vivo Purging of Circulating CD34+ Progenitor Cells in Low-Grade Lymphoma With Rituximab and High-Dose Chemotherapy
-
Progressive Intermediate Grade Non-Hodgkin’s LymphomaAfter High-Dose Therapy and Autologous Peripheral Stem-Cell Transplantation Has a High Response Rate to Rituximab
-
Use of Brachytherapy to Preserve Function in Children With Soft-Tissue Sarcomas
-
Commentary
-
Commentary
-
Randomized Comparison of COPP/ABVD vsDose- and Time-Escalated COPP/ABVD With GM-CSF Support for Advanced Hodgkin’s Disease
-
Autologous Bone Marrow Transplantation for Patients With Advanced Hodgkin’s Disease: Long-Term Follow-Up and Late Events
-
Commentary
-
Commentary
-
Innovative Breast Cancer Education Programs for African-Americans
-
New Cancer Vaccine Appears to Improve Colon Cancer Survival
-
Commentary
-
Commentary
-
506U78 in Indolent Leukemias: Pharmacokinetics of Arabinosylguanine Triphosphate Arabinosylguanine Triphosphate During Therapy
-
First Major Advance in Treatment of Lung Cancer in Years
-
IDEC-Y2B8 Radioimmunotherapy: Baseline Bone Marrow Involvement and Platelet Count Are Better Predictors of Hematologic Toxicity Than Dosimetry
-
Autologous Bone Marrow Transplantation Following Histologic Transformation of Indolent B-Cell Non-Hodgkin’s Lymphoma
-
Rituximab: Correlation Between Effector Cells and Clinical Activity in NHL
-
Rituximab: First Report of a Phase II Trial in NHL Patients With Bulky Disease
|
|
